Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a Cambridge, MA-based precision genetic medicine for rare diseases company, raised $600M in senior secured revolving facility with a bank syndicate.
JPMorgan Chase Bank, N.A. served as Administrative Agent and acted as Lead Arranger and Joint Bookrunner. The syndicate also included Barclays Bank PLC, Citizens Bank, N.A., Goldman Sachs USA, Morgan Stanley Senior Funding, Inc., Royal Bank of Canada, Fifth Third Bank, National Association, UBS AG, Stamford Branch and Bank of America.
The company intends to allocate the amount to expand operations and its R&D efforts.
Sarepta develops precision genetic medicine for rare diseases holding positions in Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs) and building a portfolio of programs across muscle, central nervous system, and cardiac diseases.
FinSMEs
17/02/2025